The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Elements in support of the ‘non-identity’ of the PGRMC1 protein with the σ2 receptor
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Subsequent studies using cancer cells with stable knockdown or overexpression of PGRMC1 challenged the conclusion of an association because neither condition changed [3H]DTG binding.
“Subsequent studies using cancer cells having a stable knockdown or overexpression of PGRMC1 challenged these conclusions since neither condition resulted in a change in binding of the σ2R radioligand, [3H]DTG17,18.”
From Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex (2018) · cites this paper as [17]
Later studies by two independent groups found that S2R binding activity was not altered irrespective of the level of PGRMC1 expressed, and full activity persisted even in the absence of PGRMC1.
“In later studies by two independent groups, however, in which PGRMC1 levels were genetically manipulated through overexpression or depletion, S2R binding activity was not altered irrespective of the level of PGRMC1 expressed, as assessed using the canonical S2R ligand tritiated di-o-tolylguanidine binding in the presence of saturating (+)-pentazocine, in a human epithelial cell line or a mouse mot”
From Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative Diseases (2023) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hayashi, T., & Su, T.-P. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051284 · Cited by 262
Izzo, N. J., Staniszewski, A., To, L., Fa, M., Teich, A. F., Saeed, F., Wostein, H., Walko, T., Vaswani, A., Wardius, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111898 · Cited by 180
Flagged first, then by citations
Research works printed but not linked: 29
- Abate, 2010, Interaction of the σ2 receptor ligand PB28 with the human nucleosome: computational and experimental probes of interaction with H2A/H2B dimer, ChemMedChem, 5, 268, 10.1002/cmdc.200900402 · DOI
- Abate, 2012, 2-Aminopyridine derivatives as potential σ2 receptor antagonists, ChemMedChem, 7, 1847, 10.1002/cmdc.201200246 · DOI
- Abate, 2011, 1-Cyclohexyl-4-(4-arylcyclohexyl)piperazines: mixed σ and human Δ(8)−Δ(7) sterol isomerase ligands with antiproliferative and P-glycoprotein inhibitory activity, ChemMedChem, 6, 73, 10.1002/cmdc.201000371 · DOI
- Abate, 2012, Classes of sigma2 (σ2) receptor ligands: structure affinity relationship (SAfiR) studies and antiproliferative activity, Curr. Pharm. Des, 18, 938, 10.2174/138161212799436485 · DOI
- Ahmed, 2012, S2R (Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling, Expert Opin. Drug Metab. Toxicol., 8, 361, 10.1517/17425255.2012.658367 · DOI · Paper page
- Al-Nabulsi, 1999, Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells, Br. J. Cancer, 81, 925, 10.1038/sj.bjc.6690789 · DOI
- Azzariti, 2006, Cyclohexylpiperazine derivative PB28, a σ2 agonist and σ1 antagonist receptor inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer, Mol. Cancer Ther., 5, 1807, 10.1158/1535-7163.MCT-05-0402 · DOI
- Balasuriya, 2014, A direct interaction between the sigma-1 receptor and the hERG voltage-gated K+ channel revealed by atomic force microscopy and homogeneous time-resolved fluorescence (HTRF®), J. Biol. Chem., 289, 32353, 10.1074/jbc.M114.603506 · DOI
- Berardi, 2009, Exploring the importance of piperazine N-atoms for σ2 receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28), J. Med. Chem., 52, 7817, 10.1021/jm9007505 · DOI
- Cobos, 2008, Pharmacology and therapeutic potential of sigma1 receptor ligands, Curr. Neuropharmacol., 6, 344, 10.2174/157015908787386113 · DOI
- Colabufo, 2006, Is the σ2 receptor a histone binding protein?, J. Med. Chem., 49, 4153, 10.1021/jm0600592 · DOI
- Hanner, 1996, Purification, molecular cloning, and expression of the mammalian sigma1-binding site, Proc. Natl. Acad. Sci. USA, 93, 8072, 10.1073/pnas.93.15.8072 · DOI
- Hornick, 2012, Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer, J. Exp. Clin. Cancer Res., 31, 41, 10.1186/1756-9966-31-41 · DOI
- Hornick, 2010, The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine, Mol. Cancer, 9, 298, 10.1186/1476-4598-9-298 · DOI
- Infantino, 2013, MEF2C exon α: role in gene activation and differentiation, Gene, 531, 355, 10.1016/j.gene.2013.08.044 · DOI
- Izzo, 2014, Alzheimer׳s therapeutics targeting amyloid beta 1-42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity, PLoS One, 9, e111899, 10.1371/journal.pone.0111899 · DOI · Paper page
- Kourrich, 2013, Dynamic interaction between sigma-1 receptor and Kv1.2 shapes neuronal and behavioral responses to cocaine, Cell, 152, 236, 10.1016/j.cell.2012.12.004 · DOI
- Mach, 1997, Sigma-2 receptors as potential biomarkers of proliferation in breast cancer, Cancer Res., 57, 156
- Matsumoto, 1995, Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism, Eur. J. Pharmacol., 280, 301, 10.1016/0014-2999(95)00208-3 · DOI
- Megalizzi, 2012, Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy, Med. Res. Rev., 32, 410, 10.1002/med.20218 · DOI
- Mir, 2012, Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients, Int. J. Cancer, 131, E1, 10.1002/ijc.26432 · DOI
- Mir, 2013, Progesterone receptor membrane component 1/Sigma-2 receptor associates with MAP1LC3B and promotes autophagy, Autophagy, 9, 1566, 10.4161/auto.25889 · DOI · Paper page
- Niso, 2013, Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: hints for collateral sensitivity, ChemMedChem, 8, 2026, 10.1002/cmdc.201300291 · DOI
- Ruoho, 2013, Will the true sigma-2 receptor please stand up?, Neuroscience
- van Waarde, 2014, Potential applications for sigma receptor ligands in cancer diagnosis and therapy, Biochim. Biophys. Acta, 10.1016/j.bbamem.2014.08.022 · DOI
- Vilner, 1995, Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines, Cancer Res., 55, 408
- Wheeler, 2000, Sigma-2 receptors as a biomarker of proliferation in solid tumours, Br. J. Cancer, 82, 1223, 10.1054/bjoc.1999.1067 · DOI · Paper page
- Xu, 2011, Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site, Nat. Commun., 2, 380, 10.1038/ncomms1386 · DOI · Paper page
- Zeng, 2012, Sigma-2 ligands induce tumour cell death by multiple signalling pathways, Br. J. Cancer, 106, 693, 10.1038/bjc.2011.602 · DOI · Paper page
Cited by
Sorted by citations
Riad, A., Zeng, C., Weng, C.-C., Winters, H., Xu, K., Makvandi, M., Metz, T., Carlin, S., & Mach, R. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-35430-3 · Cited by 147
Lizama, B. N., Kahle, J., Catalano, S. M., Caggiano, A. O., Grundman, M., & Hamby, M. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076251 · Cited by 54
Metadata
- Authors
- Abate, C., Niso, M., Infantino, V., Menga, A., & Berardi, F.
- ORCID
- Menga, Alessio
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 758
- Pages
- 16-23
- ISSN
- 0014-2999
- Cited by
- 63
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
